Codexis Stock News

The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.

REDWOOD CITY, Calif., May 11, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare.

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of

Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codex

Q1 2020 Codexis Inc Earnings Call

Wall Street securities analysts on Friday revised their ratings and price targets on several U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings. HIGHLIGHTS

R&D; revenue increased 26% to $9.6 million fueled by the Novartis and Takeda strategic collaborations Withdraws 2020 financial guidance due to uncertainty of COVID-19.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc...

Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver® platform technology transfe

Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.